A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

NCT03018665 on ClinicalTrials.gov · last registry update 2017-01-12

An unusually large phase 4: 200 participants, more than double the 75 typical for the stage. Its estimated completion date, December 2021, has passed with no update to the record. Primary outcome, as filed: Rate of Inducing Diabetes Remission. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: The First Hospital of Jilin University
Sponsor type: Other
Enrollment: 200
Started: 2017-02
Primary completion: 2021-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Rate of Inducing Diabetes Remission

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.